| DOI: 10.29090/psa.2026.01.25.8760 | Pharm Sci Asia 2026; 53(1), 92-101 |
Glycemic control effectiveness of treatment regimens containing sodium-glucose-cotransporter-2 inhibitors in Vietnamese outpatients with type 2 diabetesThuan Thi Minh Nguyen1*, Huy Van Pham1, Dat Quang Le1, Ngoc Thi Bao Le1, Thao Thi Thanh Vo2
1 Department of Biochemistry, School of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Viet Nam
2
Department of Pharmacy, Dong Nai General Hospital, Viet Nam
Sodium-glucose-agonist-2 (SGLT2) inhibitors are a new generation of oral hypoglycemic drugs that are often used in combination as a second or third-line hypoglycemic agent in the treatment of type 2 diabetes (T2D). However, the use of SGLT2 inhibitors for outpatient treatment of type 2 diabetes in Vietnam remains limited. This study aimed to investigate the drug use and glycemic control effectiveness of SGLT2 inhibitor-containing treatment regimens in T2D outpatients. A retrospective descriptive study was conducted over 3 months, compared pre- and post-treatment outcomes in 204 outpatients aged 18 years and older diagnosed with T2D treated with SGLT2 inhibitor-containing regimens at Dong Nai General Hospital from January 2023 to June 2024. The majority of patients were elderly with a median age of 67 (61.0–71.7) years, overweight and obese (over 53%), and had multiple comorbidities (hypertension and dyslipidemia were the most common). Metformin and dipeptidyl peptidase-4 inhibitors are often prescribed with SGLT2 inhibitors in combination regimens. After 3 months of treatment, fasting blood glucose (FBG) and glycated hemoglobin (HbA1c) levels of T2D outpatients were decreased from 8.77 ± 2.00 mmol/L to 7.8 ± 1.51 mmol/L for FBG and from 8.3 ± 1.41% to 7.8 ± 1.31% for HbA1c (p<0.001). Initial HbA1c levels were associated with the ability to achieve HbA1c goals (95% CI 0.20 (0.11–0.35); p<0.001). In conclusion, therapeutic regimens with SGLT2 inhibitors improved HbA1c and FBG goals of T2D outpatients. Baseline HbA1c was associated with the ability to achieve glycemic goals after treatment with SGLT2 inhibitors.
Keyword:
SGLT2 inhibitors; Type 2 diabetes; HbA1c; Fasting blood glucose; Outpatient.
Download full paper (PDF File size: 492.08 KB.)
|
